ClinicalTrials.gg
RecruitingNCT05597917TRABTRAPUpdated Nov 16, 2026

tTF-NGR Randomized Study - STS

A Phase 3 interventional study of Trabectedin and tTF-NGR in Soft Tissue Sarcoma, sponsored by Universität Münster. Recruiting at 14 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Universität Münster · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years later.
Updated Nov 16, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Sarcoma with a site in Germany — 21 open to participants now, 30 under way, 3 of them phase 3. Sarcoma · Germany.

Planned enrollment
34th of 83
126 · median 103
Started
2021
with 5 others
Phase 3
17 of 103
3 open now
Primary completion
2030-12
later than 27 of 29 live
Registered
84th of 103
by date

Among the 103 studies in Sarcoma with a site in Germany, this one is the 34th largest by planned enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2021, is one of 17 in phase 3, reaches primary completion later than 27 of the 29 other live ones, and was the 84th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

21 of the 103 studies in Sarcoma with a site in Germany are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Sarcoma with a site in Germany, or all of them as a file.
02

Study summary

In this phase III open label, controlled clinical trial patients with unresectable or metastatic soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs and CD13 positivity in central histology (grade >/= 1+) are treated to evaluate whether tTF-NGR in combination with standard trabectedin chemotherapy prolongs progression-free survival (according to iRECIST), as compared with trabectedin alone. Further objectives are to evaluate the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy with respect to the response rate and overall survival as well as to assess the safety profile of tTF-NGR combined with trabectedin. Before the randomized phase III part of the study, there was a safety run-in part. The final dose of tTF-NGR established as safe in this safety run-in part is 0.5 mg/m2 per day for 2 consecutive days following each trabectedin infusion and is used for the randomized (parallel 1:1; Arm 1: standard trabectedin, Arm 2: standard trabectedin plus tTF-NGR) phase III part of this trail. . Further dose modification for tTF-NGR is possible.

Read the detailed description

Rationale: tTF-NGR targets CD13 present in tumor-associated vasculature and on tumor cells of the majority of STS tissue samples examined; preclinical data on combination of tTF-NGR with anthracyclines and trabectedin; low competition of targeted or immune therapy in soft tissue sarcoma (STS)

Investigational Medicinal Product: Patients will receive a dose of the Investigational Medicinal Product (IMP) tTF-NGR determined to be safe within the safety run-in cohort of the study as 1-hour rate-controlled infusion (port or central venous access, 0.9 % NaCl ad 100 mL) per day for 4 or lower number of consecutive days following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday latest 9 am and on the following day, q d 22 x until disease progression or contraindications against further application.

Indication: Unresectable or metastatic STS after failure of anthracycline-containing first line treatment or with contraindications to these drugs; CD13 positivity in central histology (grade >/= 1+)

Primary objective and endpoints: The primary objective of the trial is to evaluate whether tTF-NGR in combination with standard trabectedin chemotherapy given for unresectable or metastatic soft tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs prolongs progression-free survival, as compared with trabectedin alone. The following efficacy endpoint (for the randomized phase III part) will be considered:

- Progression-free survival (PFS) according to iRECIST (Seymour L, Lancet Oncol. 2017) as judged by central radiology in a blinded fashion after end of trial.

Secondary objectives and endpoints: The secondary objective of the trial is to evaluate the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy given for unresectable or metastatic STS after failure of anthracycline-containing first line therapy or with contraindications to these drugs with respect to the response rate and overall survival as well as to assess the safety profile of tTF-NGR combined with trabectedin.

To assess the efficacy, the following measurements will be considered:

  • Overall response rate (ORR, consisting of CR and PR)
  • Disease control rate (DCR, consisting of CR, PR, and stable disease (SD) for >18 weeks)
  • Median progression-free survival (mPFS)
  • Median overall survival (mOS)
  • Overall survival (OS) rate at 12 and 18 months To assess the safety profile of tTF-NGR combined with trabectedin (for the safety run-in cohort and the main randomized phase III parts), the following safety endpoints will be considered:
  • Adverse Events (AEs) assessment based on CTCAE v.5.0.
  • Standard laboratory parameters and pharmacokinetics
  • Physical examination findings including assessment of vital signs
  • Patient reported outcomes (PRO)

Study design: Open label, randomized, controlled study in subjects with metastatic orrefractory soft tissue sarcoma. Approx. 150 patients will be screened, 126 evaluable patients are enrolled and parallel assigned in a 1:1 fashion to one of two different arms, as outlined below. Randomization will be performed using Pocock's minimization method accounting for the stratification factors CD13+ grades 1 and 2 versus CD13+ grade 3, L-sarcomas versus others (non L-sarcomas), and number of chemotherapy regimen before entry on trial: 1 versus >1.

Safety run-in part:

Before the randomized phase III part of the study, there was a safety cohort of a minimum of 6 patients obtaining at least 2 cycles each of the combination outlined in arm 2 (see below) to confirm safety of this combination (1.5 mg/m2 trabectedin plus a starting dose of 3 mg/m2 tTF-NGR). The patients were treated in-house and in sequence. In case of dose-limiting toxicity (DLT) in one patient of this cohort, a dosemodification protocol for tTF-NGR to 2 mg/m2 was carried out, and in case of further tolerability problems in one patient further deescalations in 0.5 mg/m2 steps of tTF-NGR and/or by a reduction of application days were performed. The safety part of the study is completed and the safe starting dose of tTF-NGR for the randomized phase III part of the study is 0.5 mg/m2 given on days 2 and 3. Since 6 patients tolerated >/= 2 cycles of this dose without DLT in the safety run phase, DLTs are expected to occur in \</= 10 % of the patients treated in arm 2 of the randomized part of the trial. The randomized part of the study is open after approval by the DSMB, Ethics Committee and National Competent Authority (PEI).

Randaomzied Phase III part:

ARM 1:

Trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.

ARM 2:

Patients will receive standard trabectedin according to arm 1 plus t0.5 mg/m2 tTF-NGR (1-hour ratecontrolled infusion, port central venous access, 0.9 % NaCl ad 100 mL) one days 2 and 3 following each trabectedin cycle (within max 2 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 10 am and on the following day, q d 22 x until disease progression or contraindications against further application. Further dose modification for tTF-NGR is possible (see chapeter 6.1.4 of the protocol).

As the evaluation of the study results is based on an intention-to-treat analysis, all patients after randomization will be part of the efficacy population as evaluated by central iRECIST evaluation after end of study.

Therapy in both arms can be given on an out-patient basis. All patients receive best supportive care (BSC) according to institutional guidelines. Anti-cancer activity (iRECIST modification) will be assessed (clinically and imaging) at week 9 and then every 9 weeks (independent from cycle length or number) until confirmed progression by iRECIST (iCPD). Decision on application of next cycle at week 9 will be clinical. Imaging and clinical based decision will follow. Transfer of pseudonymized imaging pictures (CD, DVD) and imaging results of a patient to the study center has to be performed after each imaging time point.

Safety assessment will be performed on an ongoing basis during study participation, including standard laboratory assessments. The incidence of AEs will be summarized by severity in all patients with at least one study drug intake.

Number of sites, countries and patients: Multicenter, up to 14 active study sites in Germany. 19 patients were treated in the phase II safety part, 126 patients will be randomized in a 1:1 ratio to receive open label Trabectedin (Arm 1) or Trabectedin plus tTF-NGR (Arm 2) in the phase III part.

Target population: Patients (18-75 years) with advanced or metastatic soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs.

ARM 1: Standard chemotherapy with Trabectidin (in-label)

ARM 2: tTF-NGR added to standard Trabectedin

Severity grading: Hematological and chemical laboratory tests, and AEs will be graded based on CTCAE v. 5.0.

Duration of Treatment: Patients will be treated in repeated cycles until definite disease progression (iRECIST; Seymour L, Lancet Oncol. 2017) in the absence of other withdrawal criteria, and as long as neither patient nor investigator requests treatment discontinuation. This defines End of Treatment (EOT).

Tumor assessments: Detailed tumor assessment visits (clinical and laboratory examinations) after start of therapy are performed before treatment start, at week 9 (+/- 1 week), followed by every 9 weeks (+/- 1 week, independent from cycle length or number) thereafter. Post-study treatment (treatment with another anti-cancer agent) is according to investigator´s choice, but is recorded in the eCRF. At iCPD (confirmed at next tumor assessment after iUPD) tumor assessments will end, but time of death will be recorded for estimation of OS. In case EOT is not determined by iCPD, tumor assessments will go on after EOT until iCPD. Survival status will be collected also for patients withdrawn from the study until death. Transfer of pseudonymized imaging pictures (CD, DVD) and imaging results of a patient to the study center has to be performed after each imaging time point.

Statistical analysis: Safety data of the safety run-in part of the study were evaluated using descriptive statistical methods.

In the primary statistical analysis of the randomized phase III part, the primary endpoint progression-free survival (PFS) according to iRECIST as judged by central blinded radiology will be compared between the two randomized treatment groups (Arm 1 versus Arm 2). The primary statistical analysis will include all randomized patients (full analysis set) and will be performed according to the intention-to-treat principle. A stratified log-rank test with stratification according to the randomization will be applied (two-sided significance level 5%, power 80%) that provides confirmatory statistical evidence.

The timing of the study will be event-driven. The primary statistical analysis will be performed at the time when 106 events in terms of PFS have been observed in total across both treatment groups. This required number of events results from the following sample size calculation. Based on the observed PFS in previous trials, PFS is expected to be exponential, and the expected median PFS is 4.6 months in the control arm (Arm 1) and 8 months in the experimental arm (Arm 2). The corresponding expected hazard ratio is HR=0.575. In a 36 months enrolment period with a rate of 3-4 patients per month, 126 patients will be recruited and randomized. The drop-out process after randomization is expected to be exponential with an up to 25% cumulative drop-out rate at month 24 (competing with the survival process). Follow-up after the last randomized patient is planned to be 12 months, after which it is expected that the required number of 106 events in terms of PFS will have occurred.

The statistical analysis of pre-specified secondary endpoints will be performed with descriptive and inferential statistical methods. Prespecified subgroup analyses will be performed with respect to stratification, L-sarcoma vs. others, FNCLCC grade (2 vs. 3), ECOG performance status (ECOG PS 0 vs. PS 1) and previously obtained Lurbinectedin/Trabectedin versus no such previous exposition. Further exploratory analyses will be performed for other relevant treatment variables (e.g. sex, age, number of treatment cycles).

Safety data will be evaluated and summarized descriptively.

Withdrawal and patient replacement criteria: The patient can withdraw consent for participation in the study at any time without disadvantages for further treatment or prejudice by the therapeutic team. The investigator can withdraw a patient if, in his or her clinical judgment, it is in the best interest of the patient or if the patient cannot comply with the protocol.

03

Conditions studied

  • Soft Tissue Sarcoma

Browse trials for

Keywords

  • tTF-NGR
  • vascular targeting
  • CD13
  • aminopeptidase N
  • Trabectedin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of all genders (female, male, diverse), with no restriction regarding ethnic or religious background age 18 - 75 years.
  2. Patients with advanced or soft-tissue sarcoma after failure of anthracycline-containing therapy (or anthracycline-containing therapy within 12 months before entry on study) or with to these drugs
  3. Patients must have histological evidence of high-grade advanced unresectable or metastatic soft tissue sarcoma (grade 2 - 3) according to the FNCLCC grading system. The following tumor types are included:

    • Dedifferentiated liposarcoma
    • Myxoid liposarcoma (high grade)
    • Pleomorphic liposarcoma
    • Adult fibrosarcoma
    • Myxofibrosarcoma (high-grade)
    • Leiomyosarcoma
    • Rhabdomyosarcoma (alveolar, pleomorphic)
    • Angiosarcoma
    • Synovial sarcoma
    • Undifferentiated sarcoma

    Tumor types not listed above may be included upon communication with Coordinating Investigator.

    The following tumor types will not be included:

    • Gastrointestinal stromal tumors (GIST)
    • Epitheloid sarcoma
    • Alveolar soft part sarcoma
    • Desmoplastic small round cell tumor
    • Chondrosarcoma
    • Osteosarcoma
    • Ewing sarcoma (including CIC-rearranged sarcoma and Sarcoma with BCOR alterations)
  4. CD13 positivity with a score of ≥ 1 (20) by central pathology (GDI Münster)
  5. Patients must have at least one unidimensionally by computed tomography as defined by criteria 1.1. Other adequate imaging procedures such as MRI are allowed. This lesion should not have been irradiated during previous treatments
  6. of at least 3 months
  7. (ECOG) Performance Status ≤ 2
  8. No contraindications for trabectedin (see attachment)
  9. Negative serum pregnancy test for females of * within 14 days of starting treatment
  10. signed and dated to participate in the study
  11. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures

    • Women of childbearing potential (WOCBP) must be using, from the screening to 3 months following the last trabectedin (Arm 1) or the last last study drug (Arm 2) administration, highly effective methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu/ctfg.html) and which include, for instance, progesteron-only or combined (estrogen- and progesteron-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomized partner or sexual abstinence. Pregnancy test will be repeated monthly. For men contraception methods should be performed for 5 months after the last application of trabectedin (Arm1) or study drug (Arm 2).Women of childbearing potential are defined as females who have experienced menarche, are not (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral salpingectomy)

Exclusion criteria

Exclusion Criteria:

  1. curative therapy available
  2. unrelated illness, which in the judgement of the investigators could compromise the patient's ability to tolerate the IMP or be likely to interfere with the study procedures or results
  3. immobilized tumor patients (wheel chair etc.) with increased risk for DVT
  4. known reactions to prior application of E. coli-derived material
  5. history of coronary heart disease, stroke, transitent ischemic attacks, pulmonary embolism, or deep vein thrombosis. For reason of mechanism of action of tTF-NGR, exclusion of patients with a history of any of the vascular conditions mentioned is important. Clinical suspicion of coronary heart disease must be further checked e.g. by cardiac MRI or myocardial scintigraphy to exclude coronary heart disease.
  6. known hereditary syndromes with elevated thromboembolic risk (FV Leiden and prothrombin mutations (G20210A), hereditary antithrombin, protein C and S deficiency, and antiphospholipid syndrome) after one or more clinical thromboembolic events
  7. patients with hereditary vascular disorders (such as Klippel-Trenauny-Weber syndrome) with increased thromboembolic risk.
  8. patients with a Khorana score of (Khorana AA, et al. J.Clin. Oncol. 2009, 27, 4839-4847, attached to this protocol) of > 3
  9. elevated Troponin T hs (> 50 ng/L) or elevated Troponin I hs before entry on study
  10. presence of active central nervous system (CNS) disease and/or CNS vascular abnormalities detected by MRI or CT
  11. no adequate bone marrow function, (ANC) \< 1.0 x 109/L, \< 50 x 109/L (for trabectedin actually \< 100 x 109/L - to be decided by the investigator on an individual patient basis) and (Hb) \< 8.0 g/dl.
  12. chronically impaired renal function or creatinine ≥ 2.0 x (ULN).
  13. inadequate liver function (alanine aminotranserase (), aspartate aminotranserase (AST), alkaline phosphatase (ALP) or total ≥ 2.5 x ULN) unless due to liver (decision by the investigator)
  14. fibrinogen \< 150 mg/dL, and/or (INR) > 1,5 (global coagulation parameters can be discussed with the Coordinating Investigator prior to entry on study)
  15. female patients with child-bearing who do not agree to exclusion of potential pregnancy by adequate testing within 48 hours prior to entry on study
  16. females of as well as fertile males who do not agree to use a highly effective form of (Pearl Index \< 1) during the study and for 3 months (females) following the last trabectedin (Arm 1) or last study drug (Arm 2) administration and 5 months (males) following the last dose of trabectedin (Arm 1) or study drug (Arm 2)
  17. women with breast-feeding activity
  18. concomitant use of any other agent (agent for which there is currently no approved indication from regulatory authorities) or any other anti-cancer drug
  19. concomitant enrolment in another clinical trial interfering with the endpoints of this study.
  20. any medical condition which could compromise participation in the study according to the investigator's assessment.
  21. prophylactic or therapeutic anticoagulation within the last 3 days
  22. presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study
  23. concurrent other than STS, unless the patient has been disease-free for at least 2 years
  24. serious, non-healing wound, ulcer or bone fracture; not completed wound healing from previous wounds and/or surgery
  25. no central venous port system in place (the option of other central venous access than a port should be discussed with the Coordinating Investigator).

NOTE: Outliers of laboratory values can be disregarded and set aside as exclusion criteria by a Coordinating Investigator´s decision. The conditions for the use of trabectedin as specified in the Summary of Product Characteristics are to be followed according to institutional guidelines for standard of care.

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
126 participants (estimated)

Study arms

  • Other
    Arm 1: Standard chemotherapy with trabectidin (in-label)

    Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.

    Drug: Trabectedin

  • Experimental
    Arm 2: tTF-NGR added to standard trabectedin

    Patients will receive standard trabectedin according to arm 1 plus 0.5 mg/m2 f tTF-NGR (1-hour rate-controlled infusion, port or central venous access, 0.9 % NaCl ad 100 mL) on days 2 and 3 following each trabectedin cycle (within max 2 hours interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 10 am and on the following day, q d 22 x until disease progression or contraindications against further application. Further dose modification for tTF-NGR is possible (see chapter 6.1.4 of the protocol).

    Drug: Trabectedin · Biological: tTF-NGR

Interventions

  • Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.

    Also known as: Yondelis

  • BiologicaltTF-NGR

    Patients will receive standard trabectedin according to arm 1 plus 0.5 mg/m2 f tTF-NGR (1-hour rate-controlled infusion, port or central venous access, 0.9 % NaCl ad 100 mL) on days 2 and 3 following each trabectedin cycle (within max 2 hours interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 10 am and on the following day, q d 22 x until disease progression or contraindications against further application. Further dose modification for tTF-NGR is possible (see chapter 6.1.4 of the protocol).

06

What researchers measure

Primary outcomes

  1. Efficacy: Prolongation of progression-free survival (PFS) according to iRECIST as judged by central radiology in a blinded fashion after end of trial.

    The primary objective of the trial is to evaluate whether tTF-NGR in combination with standard trabectedin chemotherapy given for unresectable or metastatic soft tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs prolongs progression-free survival, as compared with trabectedin alone. The following efficacy endpoint (for the randomized phase III part) will be considered: \- Progression-free survival (PFS) according to iRECIST (Seymour L, Lancet Oncol. 2017) as judged by central radiology in a blinded fashion after end of trial.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Secondary outcomes

  1. Evaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (OOR)

    To assess the efficacy, the following measurement will be considered: Overall response rate (ORR, consisting of CR and PR)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  2. Evaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (DCR)

    To assess the efficacy, the following measurement will be considered: \- Disease control rate (DCR, consisting of CR, PR, and stable disease (SD) for \>18 weeks)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  3. Evaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (mPFS)

    To assess the efficacy, the following measurement will be considered: \- Median progression-free survival (mPFS)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  4. Evaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (mOS)

    To assess the efficacy, the following measurement will be considered: \- Median overall survival (mOS)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  5. Evaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (OS)

    To assess the efficacy, the following measurement will be considered: \- Overall survival (OS) rate at 12 and 18 months

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  6. Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (AE)

    To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Adverse Events (AEs) assessment based on CTCAE v.5.0.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  7. Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Standard laboratory parameters)

    To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- laboratory parameter: Troponin T hs \[ng/l\]

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  8. Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: Height)

    To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Height \[m\]

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  9. Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: Weight)

    To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Weight \[kg\]

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  10. Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: Body surface)

    To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Body surface area \[m2\]

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  11. Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Vital sign: breathing)

    To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Vital sign: breathing rate by watching and counting \[breaths per minute\]

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  12. Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Vital sign: consciousness)

    To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Vital sign: consciousness by talking to the patient

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  13. Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Vital sign: heart rate)

    To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Vital sign: heart rate by pulse \[beats per minute\]

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  14. Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: ECOG perfomance status)

    To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: ECOG perfomance status

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  15. Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (ECG)

    To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- ECG (rythm, puls rate, Vector, P Wave, PQ time, QRS Complex, R progression from V1 to V6, QT Interval, PQ time, QRS time, T wave)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  16. Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Echocardiography)

    To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Echocardiography (diameters of both atria and left and right cardiac chambers at end-diastolic and end-systolic times \[mm\], ejection fraction \[%\], wall diameters \[mm\])

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  17. Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (PRO)

    To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Patient reported outcomes (PRO) by EORTC QLQ C30 questionnaire

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  18. Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (PK)

    To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- pharmacokinetics: AUC \[ng\*h/ml\]

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified participant data for all primary and secondary outcome measurements will be made available within 6 months of study completion

Supporting information: Study protocol

Time frame: within 6 months of study completion

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Dec 2030, 110 months after the start.

Of 24 phase 3 interventional studies under Sarcoma, half reached primary completion within 105 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 155. This study's planned 110 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Aug 2026 → Dec 2030 and completion Dec 2026 → Jun 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2021
First posted
Oct 28, 2022
StartActual
Oct 26, 2021
Primary completionEst.
Dec 2030was Aug 2026
CompletionEst.
Jun 2031was Dec 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 2 sites removed
Show 7 added (7 Germany)
  • Universitätsklinikum Augsburg · Augsburg, Germany
  • Universitätsklinikum Frankfurt · Frankfurt, Germany
  • Universitätsklinikum Hamburg-Eppendorf · Hamburg, Germany
  • Medizinische Hochschule Hannover · Hanover, Germany
  • Universitätsklinikum Jena · Jena, Germany
  • Universitätsklinikum Leipzig · Leipzig, Germany
  • LMU Klinikum · München, Germany
Show 2 removed
  • Medizinische Hochschule Hannover · Hannover, Germany
  • LMU Klinikum · Münich, Germany
Nov 16, 2026
Primary completion
Aug 2026→Dec 2030
Nov 16, 2026
Study completion
Dec 2026→Jun 2031
Nov 16, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionEfficacy: Prolongation of progression-free survival (PFS) according to iRECIST as judged by central radiology in a blinded fashion after end of trial.: how it is measured was reworded
Nov 16, 2026
Secondary outcomes
17 description edited
What changed in the outcomes
  • DescriptionEvaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (DCR): how it is measured was reworded
  • DescriptionEvaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (OS): how it is measured was reworded
  • DescriptionEvaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (mOS): how it is measured was reworded
  • DescriptionEvaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (mPFS): how it is measured was reworded
  • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (AE): how it is measured was reworded
  • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (ECG): how it is measured was reworded
  • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Echocardiography): how it is measured was reworded
  • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (PK): how it is measured was reworded
  • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (PRO): how it is measured was reworded
  • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: Body surface): how it is measured was reworded
  • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: ECOG perfomance status): how it is measured was reworded
  • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: Height): how it is measured was reworded
  • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: Weight): how it is measured was reworded
  • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Standard laboratory parameters): how it is measured was reworded
  • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Vital sign: breathing): how it is measured was reworded
  • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Vital sign: consciousness): how it is measured was reworded
  • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Vital sign: heart rate): how it is measured was reworded
Nov 16, 2026
Site contacts
Changed at 6 sites. See the sites
Show 6 sites
  • HELIOS Klinikum Bad Saarow · Bad Saarow, GermanyContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • HELIOS Klinikum Berlin-Buch · Berlin, GermanyContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • TU Dresden Medizinische Fakultät Carl Gustav Carus · Dresden, GermanyContact removed (no phone or email listed)
  • Universitätsklinikum Heidelberg · Heidelberg, GermanyContact removed (no phone or email listed)
  • Universitätsmedizin Mainz · Mainz, GermanyContact removed (no phone or email listed)
  • Klinikum rechts der Isar der technischen Universität München · München, GermanyContact J•••@mri.tum.de · •••5314→K•••@mri.tum.de · •••2677Contact person changed (no phone or email listed)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    7 sites added, 2 sites removed
    Show 7 added (7 Germany)
    • Universitätsklinikum Augsburg · Augsburg, Germany
    • Universitätsklinikum Frankfurt · Frankfurt, Germany
    • Universitätsklinikum Hamburg-Eppendorf · Hamburg, Germany
    • Medizinische Hochschule Hannover · Hanover, Germany
    • Universitätsklinikum Jena · Jena, Germany
    • Universitätsklinikum Leipzig · Leipzig, Germany
    • LMU Klinikum · München, Germany
    Show 2 removed
    • Medizinische Hochschule Hannover · Hannover, Germany
    • LMU Klinikum · Münich, Germany
    Primary completion Aug 2026→Dec 2030
    Study completion Dec 2026→Jun 2031
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionEfficacy: Prolongation of progression-free survival (PFS) according to iRECIST as judged by central radiology in a blinded fashion after end of trial.: how it is measured was reworded
    Secondary outcomes 17 description edited
    What changed in the outcomes
    • DescriptionEvaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (DCR): how it is measured was reworded
    • DescriptionEvaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (OS): how it is measured was reworded
    • DescriptionEvaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (mOS): how it is measured was reworded
    • DescriptionEvaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (mPFS): how it is measured was reworded
    • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (AE): how it is measured was reworded
    • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (ECG): how it is measured was reworded
    • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Echocardiography): how it is measured was reworded
    • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (PK): how it is measured was reworded
    • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (PRO): how it is measured was reworded
    • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: Body surface): how it is measured was reworded
    • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: ECOG perfomance status): how it is measured was reworded
    • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: Height): how it is measured was reworded
    • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: Weight): how it is measured was reworded
    • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Standard laboratory parameters): how it is measured was reworded
    • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Vital sign: breathing): how it is measured was reworded
    • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Vital sign: consciousness): how it is measured was reworded
    • DescriptionEvaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Vital sign: heart rate): how it is measured was reworded
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • HELIOS Klinikum Bad Saarow · Bad Saarow, GermanyContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • HELIOS Klinikum Berlin-Buch · Berlin, GermanyContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • TU Dresden Medizinische Fakultät Carl Gustav Carus · Dresden, GermanyContact removed (no phone or email listed)
    • Universitätsklinikum Heidelberg · Heidelberg, GermanyContact removed (no phone or email listed)
    • Universitätsmedizin Mainz · Mainz, GermanyContact removed (no phone or email listed)
    • Klinikum rechts der Isar der technischen Universität München · München, GermanyContact J•••@mri.tum.de · •••5314→K•••@mri.tum.de · •••2677Contact person changed (no phone or email listed)
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05597917
Lead sponsor
Universität Münster
Collaborators
Anturec Pharmaceuticals GmbH
Responsible party
Sponsor
First posted
Oct 28, 2022
Start date
Oct 26, 2021
Primary completion
Dec 2030 (estimated)
Completion
Jun 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Christoph Schliemann, Prof. Dr.
Contact
Christoph.Schliemann@ukmuenster.de
+49 251 83 45363
Torsten Kessler, PD Dr.
Contact
Torsten.Kessler@ukmuenster.de
+49 251 83 45363
Christoph Schliemann, Prof. Dr.
principal investigator · University Hospital Muenster (Department of Medicine A), Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion